HOME >> BIOLOGY >> NEWS
Merck CEO Raymond Gilmartin to lecture at NJIT

Raymond V. Gilmartin, chairman, president and chief executive officer of Merck and Co., Inc., will visit New Jersey Institute of Technology (NJIT) on Feb. 23 to deliver a lecture titled "A Prescription for Change in U.S. Health Care."

As more and more Americans come to rely on prescription drugs to meet their health care needs, the pharmaceutical industry is receiving increasing attention from policy makers at every level. Gilmartin will discuss the ongoing challenges facing the U.S. pharmaceutical industry, with particular focus on the areas of access, affordability, innovation and quality of care.

Merck and Co., Inc. is one of the most respected and successful drug makers in the world. Headquartered in Whitehouse Station, Merck employs nearly 64,000 people worldwide. Merck's global sales were $22.9 billion in 2004.

Since the company was founded in 1891, Merck researchers have pioneered innovations for treating serious diseases a tradition that produced such major medical advances as penicillin, streptomycin and cortisone, among others.

Merck is also well known for its philanthropy. For nearly 20 years, Merck has donated a drug to treat river blindness in Africa and Latin America. The company responded to the recent tsunami disaster by pledging more than $10 million in aid and supplies. Nearer to home, Merck has contributed more than $20 million to the Merck Institute for Science Education, which partners with New Jersey and Pennsylvania school districts to improve science and math education.

Prior to joining Merck in 1994, Gilmartin was chairman, president and chief executive officer of Becton Dickinson. He received a bachelor's degree in electrical engineering from Union College in 1963 and an MBA from Harvard Business School in 1968. He serves on the boards of General Mills, Inc. and the Microsoft Corporation. He is chairman of the Board of Directors of The United Negro College Fund and is a trustee of the Healthcare Le
'"/>

Contact: Robert Florida
florida@njit.edu
973-596-5203
New Jersey Institute of Technology
16-Feb-2005


Page: 1 2

Related biology news :

1. Merck and AAAS announce 2007 winners of Outstanding Undergraduate Research Programs
2. Harvard Medical signs agreement with Merck to develop potential therapy for macular degeneration
3. Merck and AAAS announce 2006 winners for Outstanding Undergraduate Research Programs
4. Researchers gain support from Merck Sharp & Dohme for novel area of diabetes research
5. Nobel Laureate Sydney Brenner receives 2005 UCSD/Merck Life Science Achievement Award
6. Merck / AAAS announce 2005 winners for outstanding undergraduate research programs
7. Protein tyrosine phosphatases to be topic of ASBMB-Merck Award lecture
8. Award lectures for ASBMBs 2007 Annual Meeting
9. AACR establishes new lecture in honor of Princess Takamatsu
10. National Academies Advisory: March 5 lecture on ocean acidification
11. Becker to deliver plenary lecture at plasma science meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
Breaking Biology Technology:
Cached News: